Compare VRME & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRME | BCDA |
|---|---|---|
| Founded | 1999 | N/A |
| Country | United States | United States |
| Employees | 30 | 21 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.0M | 12.9M |
| IPO Year | N/A | N/A |
| Metric | VRME | BCDA |
|---|---|---|
| Price | $0.70 | $1.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $1.50 | ★ $25.00 |
| AVG Volume (30 Days) | 55.6K | ★ 105.1K |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $36.85 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.59 | $1.00 |
| 52 Week High | $1.51 | $2.49 |
| Indicator | VRME | BCDA |
|---|---|---|
| Relative Strength Index (RSI) | 31.07 | 43.44 |
| Support Level | $0.64 | $1.10 |
| Resistance Level | $0.93 | $1.30 |
| Average True Range (ATR) | 0.05 | 0.05 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 17.89 | 38.86 |
VerifyMe Inc is a logistics company that specializes in time and temperature-sensitive products, as well as providing brand protection and enhancement solutions. The company operates through two reportable business segments: Precision Logistics offers a value-added service provider for time and temperature-sensitive parcel management. Using a proprietary IT platform, it provides real-time information and analysis to mitigate supply chain flow interruption, delivering last-mile resolution for key markets, including the perishable healthcare and food industries; and the Authentication segment specializes in anti-counterfeit and brand protection. The Precision Logistics segment derives the majority of the revenue.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).